ASCO Breakthroughs, Gene Therapy Stumbles, and Omada's IPO debut — This Week in Biotech #55

Subscribe to Biotech Blueprint here.In this week’s episode, I break down the biggest stories shaping the biotech and pharma landscape from May 30 to June 7, 2025.🔬 ASCO 2025 delivered big results in oncology, with AstraZeneca’s camizestrant, Summit’s ivonescimab, and Gilead/Merck’s TROP-2 ADC combo showing major clinical gains.💰 Strategic dealmaking followed the data, including a $1.5B BioNTech/Bristol Myers deal and Sanofi’s $9.1B Blueprint Medicines acquisition.💊 Regeneron staked a claim in obesity, pushing beyond GLP-1s with a muscle-sparing antibody combo and a dual agonist licensing deal.🧬 Gene therapy remains scientifically strong but commercially uncertain-Regenxbio soared in the clinic but dipped on Wall Street.📈 Markets showed a cautious rebound, with XBI and IBB edging up and Omada Health making a strong IPO debut under ticker OMDA.We also spotlight clinical standouts from Moderna and more.If you enjoy this content, subscribe to the newsletter below.

There are no comments yet.

Please log in to write the first comment.